Oncogene Proteins, Fusion
"Oncogene Proteins, Fusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
| Descriptor ID |
D015514
|
| MeSH Number(s) |
D12.776.602.500.500 D12.776.624.664.500
|
| Concept/Terms |
Oncogene Proteins, Fusion- Oncogene Proteins, Fusion
- Fusion Oncogene Proteins
- Proteins, Fusion Oncogene
- Oncogene Proteins, Chimeric
- Fusion Proteins, Oncogene
- Oncogene Fusion Proteins
- Proteins, Oncogene Fusion
- Chimeric Oncogene Proteins
- Proteins, Chimeric Oncogene
- Chimeric Proteins, Oncogene
- Oncogene Chimeric Proteins
- Proteins, Oncogene Chimeric
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Fusion".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Fusion".
This graph shows the total number of publications written about "Oncogene Proteins, Fusion" by people in this website by year, and whether "Oncogene Proteins, Fusion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 4 | 0 | 4 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 0 | 3 |
| 1999 | 5 | 1 | 6 |
| 2000 | 3 | 2 | 5 |
| 2001 | 6 | 3 | 9 |
| 2002 | 6 | 3 | 9 |
| 2003 | 3 | 5 | 8 |
| 2004 | 7 | 1 | 8 |
| 2005 | 0 | 3 | 3 |
| 2006 | 8 | 3 | 11 |
| 2007 | 8 | 4 | 12 |
| 2008 | 9 | 4 | 13 |
| 2009 | 6 | 7 | 13 |
| 2010 | 9 | 3 | 12 |
| 2011 | 14 | 5 | 19 |
| 2012 | 12 | 16 | 28 |
| 2013 | 14 | 6 | 20 |
| 2014 | 11 | 8 | 19 |
| 2015 | 12 | 5 | 17 |
| 2016 | 11 | 4 | 15 |
| 2017 | 13 | 3 | 16 |
| 2018 | 11 | 11 | 22 |
| 2019 | 12 | 4 | 16 |
| 2020 | 12 | 12 | 24 |
| 2021 | 15 | 7 | 22 |
| 2022 | 3 | 15 | 18 |
| 2023 | 2 | 9 | 11 |
| 2024 | 8 | 15 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Proteins, Fusion" by people in Profiles.
-
Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
An optimized workflow of full-length transcriptome sequencing for accurate fusion transcript identification. RNA Biol. 2024 01; 21(1):122-131.
-
MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024 Oct 29; 15(1):9341.
-
Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2024 Oct 20; 77(11):751-755.
-
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clin Cancer Res. 2024 Oct 15; 30(20):4572-4583.
-
RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proc Natl Acad Sci U S A. 2024 Sep 03; 121(36):e2405543121.
-
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol. 2024 Oct; 99(10):1959-1968.
-
BCR::ZNF711 and BCR::CYLC2 Fusions: Novel BCR Fusions Expanding the Molecular Spectrum of Gene Fusions in Melanoma. Am J Dermatopathol. 2024 Nov 01; 46(11):797-799.
-
TPPP-BRD9 fusion-related gallbladder carcinomas are frequently associated with intracholecystic neoplasia, neuroendocrine carcinoma, and a distinctive small tubular-type adenocarcinoma commonly accompanied with a syringomatous pattern. Hum Pathol. 2024 08; 150:67-73.
-
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. J Clin Oncol. 2024 Nov; 42(31):3725-3734.